Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

eprenetapopt (APR-246)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Aprea

Drug class:

p53 reactivator

Related drugs:

‹

›

TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	APR-246 Sensitive: B - Late Trials APR-246 Sensitive : B	APR-246 Sensitive: B - Late Trials APR-246 Sensitive : B
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	APR-246 Sensitive: B - Late Trials APR-246 Sensitive : B	APR-246 Sensitive: B - Late Trials APR-246 Sensitive : B
TP53 mutation	Non Small Cell Lung Cancer	TP53 mutation	Non Small Cell Lung Cancer	pembrolizumab + APR-246 Sensitive: C3 – Early Trials pembrolizumab + APR-246 Sensitive : C3	pembrolizumab + APR-246 Sensitive: C3 – Early Trials pembrolizumab + APR-246 Sensitive : C3
TP53 mutation	Solid Tumor	TP53 mutation	Solid Tumor	pembrolizumab + APR-246 Sensitive: C3 – Early Trials pembrolizumab + APR-246 Sensitive : C3	pembrolizumab + APR-246 Sensitive: C3 – Early Trials pembrolizumab + APR-246 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	venetoclax + APR-246 Sensitive: C3 – Early Trials venetoclax + APR-246 Sensitive : C3	venetoclax + APR-246 Sensitive: C3 – Early Trials venetoclax + APR-246 Sensitive : C3
TP53 273H	Lung Cancer	TP53 273H	Lung Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
FGF4 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	FGF4 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
FGF3 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	FGF3 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	FGF19 amplification + HRAS Q61R + TP53 672+2T>G	Prostate Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
TP53 mutation	Esophageal Adenocarcinoma	TP53 mutation	Esophageal Adenocarcinoma	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
TP53 mutation	Acute Lymphocytic Leukemia	TP53 mutation	Acute Lymphocytic Leukemia	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
TP53 R248Q	Myelodysplastic Syndrome	TP53 R248Q	Myelodysplastic Syndrome	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
TP53 R248Q	Acute Myelogenous Leukemia	TP53 R248Q	Acute Myelogenous Leukemia	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
TP53 mutation	Triple Negative Breast Cancer	TP53 mutation	Triple Negative Breast Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
TP53 R280K + BRCA wild-type	Triple Negative Breast Cancer	TP53 R280K + BRCA wild-type	Triple Negative Breast Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
BRCA2 Y1655* + TP53 mutation	Ovarian Cancer	BRCA2 Y1655* + TP53 mutation	Ovarian Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D
BRCA2 mutation + TP53 D816Y	Ovarian Cancer	BRCA2 mutation + TP53 D816Y	Ovarian Cancer	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D	APR-246 Sensitive: D – Preclinical APR-246 Sensitive : D